Nurix Therapeutics, Inc. (NASDAQ:NRIX) Expected to Post Quarterly Sales of $9.59 Million

Equities analysts expect that Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) will announce $9.59 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Nurix Therapeutics’ earnings, with the highest sales estimate coming in at $11.54 million and the lowest estimate coming in at $8.00 million. Nurix Therapeutics posted sales of $7.09 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 35.3%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Nurix Therapeutics will report full-year sales of $49.54 million for the current fiscal year, with estimates ranging from $32.00 million to $70.05 million. For the next fiscal year, analysts anticipate that the business will report sales of $71.04 million, with estimates ranging from $35.30 million to $105.95 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Nurix Therapeutics.

Nurix Therapeutics (NASDAQ:NRIX – Get Rating) last released its quarterly earnings data on Thursday, April 7th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Nurix Therapeutics had a negative return on equity of 36.42% and a negative net margin of 394.21%.

NRIX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Nurix Therapeutics in a report on Wednesday, January 5th. Robert W. Baird lowered their price target on Nurix Therapeutics from $49.00 to $41.00 in a report on Friday, January 28th. Zacks Investment Research upgraded Nurix Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright initiated coverage on Nurix Therapeutics in a report on Wednesday, December 29th. They issued a “buy” rating and a $62.00 price target for the company. Finally, Wells Fargo & Company lowered their price target on Nurix Therapeutics from $28.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $47.00.

A number of large investors have recently bought and sold shares of NRIX. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $117,000. Ensign Peak Advisors Inc lifted its position in shares of Nurix Therapeutics by 512.0% during the fourth quarter. Ensign Peak Advisors Inc now owns 4,890 shares of the company’s stock worth $142,000 after purchasing an additional 4,091 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $178,000. Grace Capital lifted its position in shares of Nurix Therapeutics by 47.2% during the third quarter. Grace Capital now owns 6,727 shares of the company’s stock worth $190,000 after purchasing an additional 2,158 shares during the last quarter. Finally, Fiduciary Trust Co. bought a new position in shares of Nurix Therapeutics during the third quarter worth about $200,000. 87.30% of the stock is owned by institutional investors.

NRIX stock opened at $12.37 on Tuesday. Nurix Therapeutics has a 52 week low of $12.34 and a 52 week high of $37.42. The firm has a market cap of $554.84 million, a P/E ratio of -4.06 and a beta of 2.74. The business’s fifty day moving average price is $15.24.

About Nurix Therapeutics (Get Rating)

Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Further Reading